Toxicology News and Research

Latest Toxicology News and Research

XenoPort initiates XP23829 Phase 1 study in healthy adults

XenoPort, Inc. announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.

24 Jul 2012

Synthetic triterpenoids block development of Parkinson's disease

A new and powerful class of antioxidants could one day be a potent treatment for Parkinson's disease, researchers report.

23 Jul 2012

Protein associated with Huntington’s and other neurodegenerative diseases has several brain-specific forms

A protein essential for metabolism and recently associated with neurodegenerative diseases also occurs in several brain-specific forms. This discovery emerged in the course of a research project funded by the Austrian Science Fund FWF, the findings of which have now been published in the journal Human Molecular Genetics.

23 Jul 2012

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

A Marshall University faculty member has been awarded a three-year, $426,000 grant by the National Institutes of Health (NIH) to further her lung cancer research.

21 Jul 2012

WTG to launch ‘Early Drug Development Summit’ in Berlin

With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.

16 Jul 2012

Next generation predictive 3D cell toxicity assays to be developed by Medicyte GmbH and Reinnervate Ltd

Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte (inventors of the upcyte® technology) and Reinnervate (market leaders in the growing field of 3D cell culture) said they will work together to combine their upcyte® and Alvetex®Scaffold technologies to bring next generation cell bases assays to the biopharma and academic research markets.

9 Jul 2012

Safe optimal concentration of propolis against radiation-induced damage

Researchers determined the amount of propolis offering maximum protection against ionised radiations without being toxic to blood cells.

7 Jul 2012

Toxins and cell death: Interview with Professor Denise Montell

There are multiple kinds of cell death. Cells can undergo programmed cell death, which is a series of events that undergoes a predictable order at certain times during development.

6 Jul 2012

Study represents starting point for future clinical applications using propolis

A team of researchers from the University of Valencia, the Universitat Politècnica de València, the University Hospital La Fe and the Universitat Autònoma de Barcelona conducted in vitro studies of cytotoxicity (cellular affection) to assess the optimal concentration level of propolis in which this natural substance extracted from bee resin would offer the maximum protection against ionised radiation and not be toxic for blood cells.

6 Jul 2012

New toxicology testing method requires lesser number of fish

A new way of testing the safety of natural and synthetic chemicals has been developed by scientists with funding from the Biotechnology and Biological Sciences Research Council (BBSRC). Their research, published today in the journal Ecotoxicology, could reduce the number of fish needed to test the toxicity of a range of chemicals including pharmaceuticals and environmental pollutants.

30 Jun 2012

Prenatal exposure to PCBs impacts reproductive function in offspring

Prenatal exposure to the environmental contaminants polychlorinated biphenyls, or PCBs, causes long-term changes to the developing brain that have adverse effects on reproductive function later in life, a new study finds. Results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

28 Jun 2012

Seahorse Bioscience launches XF Palmitate-BSA FAO Reagent for FAO assays

Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

27 Jun 2012

BV treatment: full enrolment for phase 2 and first phase 3 trial

Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) is pleased to report that recruitment is now 100% complete for its Phase 2 clinical trial to investigate the ability of VivaGel® to prevent the recurrence of BV, and also for the first of two pivotal Phase 3 studies of VivaGel® for the treatment of BV.

25 Jun 2012

FDA issues CRL to Repligen's RG1068 NDA for treatment of pancreatitis

Repligen Corporation today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for RG1068.

23 Jun 2012

Long QT Syndrome may cause unexplained ExD deaths

The headlines are often filled with this scenario: a person displaying violent, bizarre and agitated behavior is subdued by law enforcement personnel and later dies in custody. It appears to be a case of police brutality - but is it? According to William P. Bozeman, M.D., an emergency medicine physician at Wake Forest Baptist Medical Center, some of these deaths may be caused by an abnormal cardiac condition called Long QT Syndrome, compounded by a situation of Excited Delirium (ExD) Syndrome.

21 Jun 2012

Study identifies critical neurological factor in aggression

Pathological rage can be blocked in mice, researchers have found, suggesting potential new treatments for severe aggression, a widespread trait characterized by sudden violence, explosive outbursts and hostile overreactions to stress.

20 Jun 2012

Thermo Fisher Scientific introduces research-grade FT-IR system

Thermo Fisher Scientific Inc., the world leader in serving science, extended its leading FT-IR spectrometry platform by introducing the first research-grade FT-IR system designed for simple one-touch operation.

From Thermo Fisher Scientific Inc. 18 Jun 2012

ABL to perform process development and cGMP manufacturing of recombinant scuPA

Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung.

14 Jun 2012

New set of computer models predicts negative side effects in current drugs

A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature.

12 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012